Interdisciplinary Association for Population Health Science

Helius Medical Technologies to Present at the 2023 Interdisciplinary Association of Functional Neuroscience and Rehabilitation Conference

Retrieved on: 
Wednesday, September 13, 2023
Management of multiple sclerosis, Health, Gait, Pons, HSDT, Stroke, Therapy, Interdisciplinary Association for Population Health Science, Rehabilitation, Multiple sclerosis, Movement, Science, Neuroscience, Patient, Person-centered therapy, Conference, Nursing

NEWTOWN, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Antonella Favit-Van Pelt, M.D., Ph.D., Helius’ Chief Medical Officer, will present at the Interdisciplinary Association of Neuroscience and Rehabilitation (IAFNR) Conference from September 28 to October 1, 2023. The IAFNR Conference is a four-day virtual event intended for neuroscience experts, including movement and neuromuscular disorder specialists, physical therapists, and occupational therapists.

Key Points: 
  • -- Presentation to educate on Portable Neuromodulation Stimulator (PoNS®) Therapy, highlighting the differentiation from other neuromodulation technologies, and the science behind its effectiveness, clinical data, safety profile --
    NEWTOWN, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Antonella Favit-Van Pelt, M.D., Ph.D., Helius’ Chief Medical Officer, will present at the Interdisciplinary Association of Neuroscience and Rehabilitation ( IAFNR ) Conference from September 28 to October 1, 2023.
  • The IAFNR Conference is a four-day virtual event intended for neuroscience experts, including movement and neuromuscular disorder specialists, physical therapists, and occupational therapists.
  • “The field of neuromodulation-based healthcare is evolving rapidly, and we believe that PoNS Therapy™ is a groundbreaking treatment for people suffering from balance or gait impairment.
  • Our goal has always been to bring this impactful technology to as many qualifying patients as possible, and this forum is an excellent platform to create awareness and engage leading practitioners in neurorehabilitation.”
    Details of the presentation are as follows:

SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer

Retrieved on: 
Wednesday, September 6, 2023
Contact tracing, University, Internal medicine, Public, EVP, COVID-19, Smallpox, Infection, COVID, CMO, Harvard College, CDC, MPOX, SIGA Technologies, Interdisciplinary Association for Population Health Science, Risk, Chief Medical Officer (Australia), Weill Cornell Medicine, Safety, Management, Pharmaceutical industry, Vaccine

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Jay K. Varma has joined SIGA as Executive Vice President and Chief Medical Officer (CMO).

Key Points: 
  • NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Jay K. Varma has joined SIGA as Executive Vice President and Chief Medical Officer (CMO).
  • He will also continue to serve as a director of the SIGA Board of Directors.
  • “In his new additional role as EVP and Chief Medical Officer, he will be positioned to apply even more of his outstanding insight and experience to support our advocacy efforts.”
    As EVP and CMO, Dr. Varma will lead medical affairs.
  • SIGA plays a central role in helping countries around the world understand and respond to potential outbreaks of smallpox, MPOX and other orthopox viruses,” said Dr. Varma.

Leaders from RadEqual and the AAWR Sign MOU, Solidifying Commitment to Advance Opportunities in Radiology

Retrieved on: 
Monday, May 8, 2023
Faculty, Informatics, American College of Radiology, Executive, Partnership, Pediatrics, Senior, Health, Woman, Drexel University College of Medicine, Mentorship, Equity, ELAM, Organization, American Association for Women in Radiology, Interdisciplinary Association for Population Health Science, MOU, Diversity, Weill Cornell Medicine, American College, ELH, Female, Nursing, Management, Radiology

WASHINGTON, May 8, 2023 /PRNewswire-PRWeb/ -- Leaders from RadEqual, an organization that fosters networking and mentorship opportunities for leaders in radiology, informatics, and IT management, and the American Association for Women in Radiology (AAWR) today signed a Memorandum of Understanding (MOU) at the 2023 American College of Radiology's annual meeting in Washington D.C. The two-year MOU will merge both parties into a formal agreement that will support increased collaboration and promote a shared pursuit of creating educational initiatives for the broader radiology community.

Key Points: 
  • "It is part of the AAWR's mission and purpose to create networking and mentorship opportunities for leaders in the radiology field," said Dr. Amy Patel, President, AAWR.
  • In August 2022, RadEqual launched a webinar series sponsored by Intelerad , and now the AAWR, on overcoming the mid-career stall.
  • Webinar attendees have the opportunity to learn from some of the healthcare industry's most renowned leaders.
  • To learn more about the AAWR's President Dr. Amy Patel, visit aawr.org/Amy-K-Patel-MD , and follow her on LinkedIn , Twitter and Instagram .

Health Foundation of South Florida Invests $2 Million in Florida Universities to Advance Health Equity in Underserved Communities

Retrieved on: 
Friday, February 17, 2023
Center for Digital Research and Scholarship, Health Foundation, Person, Memorial Hermann Health System, Population health, Physician, NSU, University, GuideWell, Violence, UM, Interdisciplinary Association for Population Health Science, JHS, Workforce, Miami Dade College, Research, Social change, Professor, CDC, Nova Southeastern University, Health equity, Policy, Modern Healthcare, Jackson Health System, Allopathic medicine, Disease, Management, The Colorado Health Foundation, Centers for Disease Control and Prevention, Partnership, Environment, University of Miami, Nursing, Health, Entrepreneurship, Health care, Broward, Collaboration, Strategy

MIAMI, Feb. 17, 2023 /PRNewswire/ -- The Health Foundation of South Florida, the region's largest philanthropic organization focused on achieving health equity in historically underserved communities, announced it is investing $2 million in two Florida universities to foster research, innovation, community engagement, and leadership development aimed at identifying and addressing barriers to optimal health in low-income communities in Miami-Dade and Broward counties.

Key Points: 
  • UM will partner with Jackson Health System, Miami-Dade County's public hospital, and Health Choice Network, a nationally recognized nonprofit that works with 25 health centers in Florida.
  • The Health Foundation of South Florida Community-Academic Collaborative at the University of Miami will support five community-academic teams charged with developing and implementing data-driven, community-engaged projects to improve health outcomes in underserved communities.
  • "The grant from the Health Foundation provides a unique opportunity for diverse stakeholders to work collaboratively to advance health equity.
  • In addition, the group will build a health equity index and dashboard that enables the monitoring of health equity status in South Florida.

FDA Agrees to Expanded Access Program for the BioVentrix® Revivent TC® System for the Treatment of Ischemic Heart Failure

Retrieved on: 
Tuesday, January 24, 2023
EAP, US Foods, Revivent, HIV disease progression rates, Execute Direct Access Program, Policy, Cleveland Clinic, ALIVE, Heart failure, FDA, Rational living therapy, Mount Sinai, Icahn School of Medicine at Mount Sinai, SAN, Patient, Interdisciplinary Association for Population Health Science, Food, Heart, Microsoft Access, Pharmaceutical industry, MD, Cardiology, Medicine

SAN RAMON, Calif., Jan. 24, 2023 /PRNewswire/ -- BioVentrix®, Inc., a privately held medical device company focused on the development of less invasive therapies to directly treat the dilated left ventricle and reverse the left ventricular remodeling process of progressive heart failure, today announced the US Food and Drug Administration (FDA) has approved its application for an Expanded Access Program (EAP) for Revivent TC® System.

Key Points: 
  • The procedure, referred to as Less Invasive Ventricular Enhancement (LIVE®) therapy, utilizes myocardial micro-anchor implants to reconstruct the dilated left ventricle to produce a more efficient chamber.
  • The approval for an Expanded Access Program follows the successful completion of enrollment in the ALIVE (American Less Invasive Ventricular Enhancement) Trial, a prospective, multi-center, dual-arm pivotal study of the BioVentrix Revivent TC System.
  • "Heart failure patients with reduced ejection fraction (HFrEF) that are not responsive to standard-of-care therapies may now have access to LIVE Therapy, currently under investigation."
  • "Patients with heart failure with high-risk features including significant shortness of breath despite medical management remain at high risk for disease progression and life-threatening events."

Shockwave Medical Announces Agreement to Acquire Neovasc

Retrieved on: 
Tuesday, January 17, 2023
Cardiovascular disease, C2, Chest pain, Piping and plumbing fitting, IVL, CVR, TSX, FDA, ANOCA, FACC, Cardiology, Interdisciplinary Association for Population Health Science, U.S. FDA, Growth, Patient, VWAP, Canada Business Corporations Act, Investigational device exemption, Angina, Pharmaceutical industry, Security (finance), Video game, MD, Policy, Shock wave

SANTA CLARA, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced it has entered into a definitive agreement to acquire Neovasc Inc. (NASDAQ,TSX:NVCN), a company focused on the minimally invasive treatment of refractory angina.

Key Points: 
  • alone, up to 300,000 new patients with obstructive coronary disease who are ineligible for conventional revascularization experience refractory angina, despite guideline-directed medical therapy.
  • Directors and executive officers of Neovasc and related parties, holding an aggregate of approximately 9.23% of the Neovasc shares currently outstanding (on a non-diluted basis) have entered into support and voting agreements with Shockwave.
  • Shockwave Medical management will host a conference call today at 8:30 a.m.
  • ET to discuss its definitive agreement to acquire Neovasc.

New Study in JNCCN Presents Evidence for 'Tough Conversations' Around Racism in Access to Cancer Care

Retrieved on: 
Wednesday, November 9, 2022
Journal of the National Comprehensive Cancer Network, Ovarian cancer, MBA, Diagnosis, Review, Report, Oncology, Health, NCCN, Interdisciplinary Association for Population Health Science, Patient, Bioethics, Vanderbilt-Ingram Cancer Center, Department, Data, Strathcona County, Mortality, Population, Survival, Duke University School of Medicine, Harborside, Cancer, Decision-making, National Comprehensive Cancer Network, Policy, Education, Doctor of Philosophy, Hospital, Caregiver, Duke Cancer Institute, Medicine, Employment, Solution, Comorbidity, Research, Public policy, White, Health insurance, Medical device, Birth control, MD, Medicare

PLYMOUTH MEETING, Pa., Nov. 9, 2022 /PRNewswire/ -- New research in the November 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network examined whether people with ovarian cancer were being treated based on very specific recommendations regarding comprehensive staging surgery and the recommended minimum cycles of systemic therapy from evidence-based, expert consensus NCCN Guidelines. The findings showed clear disparities based on patients' race, ability to pay, and the availability of specialists/cancer centers in their area—significantly impacting treatment course, which can affect survival. Out of 6,632 patients studied, 23.8% of non-Hispanic White patients received fully guideline-concordant surgery and chemotherapy compared to only 14.2% of non-Hispanic Black patients. Racial disparities remained after adjusting for the assessed healthcare access issues, including the ability to pay for care and having access to local specialists.

Key Points: 
  • Racial disparities remained after adjusting for the assessed healthcare access issues, including the ability to pay for care and having access to local specialists.
  • "This study demonstrated, similar to many other studies, thatnon-Hispanic Black ovarian cancer patients were less likely than non-Hispanic White ovarian cancer patients to receive NCCN Guidelines-based care.
  • Complimentary access to " Healthcare Access Dimensions and Guideline-Concordant Ovarian Cancer Treatment: SEER-Medicare Analysis of the ORCHiD Study " is available until February 10, 2023.
  • More than 25,000 oncologists and other cancer care professionals across the United States readJNCCNJournal of the National Comprehensive Cancer Network.

Komodo Health Platform Selected by Stanford Medicine for Health Outcomes Research During the COVID-19 Pandemic

Retrieved on: 
Thursday, August 4, 2022
COVID-19, Technology, Research, Venture Capital, Software, Health, General Health, Data Management, Science, Komodo, Sentinel, Machine learning, Intelligence, Industry, Algorithm, AI, Technology, Clinical trial, Infection, Entrepreneurship, Research, Obstetrics, Health, Health policy, COVID-19, Stanford University School of Medicine, Gynaecology, Education, COVID-19 testing, List of life sciences, Decision-making, Gaps, News, Interdisciplinary Association for Population Health Science, Population health, Pediatrics, Pharmaceutical industry, Medical device

Today, Komodo Health announced that its platform will be used in studies led by Stanford Medicine focused on the short- and long-term health impacts of COVID-19.

Key Points: 
  • Today, Komodo Health announced that its platform will be used in studies led by Stanford Medicine focused on the short- and long-term health impacts of COVID-19.
  • Initial research projects using Sentinel will explore the real-world impact of the COVID-19 pandemic on health outcomes among different patient populations, including disparities in care and social determinants of COVID-19 testing, COVID-19 vaccinations, and how cancer survival, treatment, and outcomes changed during the pandemic.
  • Todays news is the latest example of how Komodo is collaborating with academic researchers and strengthening the industrys ability to produce high-fidelity Health Economic Outcomes Research (HEOR) with the most comprehensive and representative data available.
  • Komodos platform provides access to comprehensive real-world data for academic research and illuminates critical patterns in treatment, disease risk, and real-world outcomes.

Intelerad Focuses on Cloud-Enabled Enterprise Imaging, AI, and Health Equity at SIIM 2022

Retrieved on: 
Tuesday, June 7, 2022
Cloud, Woman, Enterprise imaging, Privacy, Time, Radiology, Research Institute of Healthcare Organization and Medical Management of Moscow Department of Healthcare, Product, LinkedIn, Software, Product management, Informatics, Partnership, Society, Senior, Workload, Annual general meeting, Weill Cornell Medicine, Solution, Health, Patient, Hospital, Ambra Health, Twitter, Panner, Booth, Efficiency, Pursuit, Interdisciplinary Association for Population Health Science, Medicine, Medical imaging, Management, Marketing, KLAS, Medicine

RALEIGH, N.C. and MONTREAL, June 7, 2022 /PRNewswire-PRWeb/ -- At the 2022 Society for Imaging Informatics in Medicine (SIIM) Annual Meeting in Kissimmee, Florida from June 9-11, Intelerad Medical Systems™, a global leader in medical image management solutions, will showcase its recently launched Enterprise Imaging and Informatics Suite at Booth #411.

Key Points: 
  • From image management to structured reporting and analytics, the Enterprise Imaging and Informatics Suite aims to simplify workflows and reduce costs, all while also improving patient outcomes," said Morris Panner, President of Intelerad .
  • "We look forward to connecting with the SIIM community this week to further demonstrate how our innovative technology can drive efficiency, provider excellence, and better patient care."
  • Additionally, Intelerad will be co-sponsoring the RADequal Awards during the SIIM Welcome Reception from 6-7:30 p.m. on June 9.
  • Intelerad's award-winning enterprise imaging solutions have been recognized globally by KLAS, with Intelerad's Ambra Health ranked #1 for Image Exchange in the 2022 Best in KLAS: Software and Professional Services report .

Neighborhoods Most Affected by Racism, Inequities and COVID-19 Pandemic Stressors at a Greater Risk for Preterm Births, Mount Sinai Study Finds

Retrieved on: 
Monday, May 2, 2022
COVID-19, Gestation, Preterm birth, Icahn School of Medicine at Mount Sinai, Mortality, Woman, NEW, Interdisciplinary Association for Population Health Science, Pregnancy, Racism, Centre for Human Reproductive Science, Research, Roger Hawkins (drummer), Patient, Color, Associate, Infant, Physician, Public Health Research Institute, Unemployment, Gynaecology, Mount Sinai Health System, Face, MPH, Global Health, Interview, American Journal, Risk, Birth control, Pharmaceutical industry, Animal, Policy, White, Doctor of Philosophy, Medicine, Obstetrics

NEW YORK, May 2, 2022 /PRNewswire-PRWeb/ -- The cohort study from Mount Sinai follows women through pregnancy and birth to study if a SARS-CoV-2 infection, the virus that causes COVID-19, is associated with poor pregnancy outcomes.

Key Points: 
  • Bottom Line: The cohort study follows women through pregnancy and birth to study if a SARS-CoV-2 infection, the virus that causes COVID-19, is associated with poor pregnancy outcomes.
  • Results: The study concluded that structural racism is associated with both increased risk of COVID-19 infection and preterm births.
  • Women in mostly Black, low-income neighborhoods had nearly three times the risk of COVID-19 infection as those in White, wealthy neighborhoods.
  • To schedule an interview with the researcher, please contact the Mount Sinai Press Office at [email protected] or 347-346-3390.